Curis, Inc.
NASDAQ: CRIS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Dentzer
- Employees
- 24
- Headquarters
- Lexington, United States
- IPO year
- 2000
- Market cap
- $4.5M
- Website
- https://www.curis.com
Loading CRIS…
Loading profile data…Frequently asked questions about CRIS
What does Curis, Inc. (CRIS) do?
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed...
Where does CRIS trade?
Curis, Inc. (CRIS) trades on the NASDAQ.
What sector is CRIS in?
Curis, Inc. (CRIS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Curis, Inc.?
James Dentzer is the chief executive officer of Curis, Inc. (CRIS).
Where is Curis, Inc. headquartered?
Curis, Inc. is headquartered in United States.
Does CRIS pay a dividend?
Curis, Inc. (CRIS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRIS go public?
Curis, Inc. (CRIS) completed its initial public offering in 2000.